Tapestry Pharmaceuticals, Inc.

BOULDER, Colo., Dec. 21 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it received notice on December 18, 2007 from the Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore not in compliance with Marketplace Rule 4310(c)(4). In accordance with the Nasdaq Marketplace Rule 4310(c)(8)(D), Tapestry has until June 16, 2008, which is 180 calendar days from December 18, 2007, to regain compliance. This notification does not have immediate affect on the listing of the Company's common stock. Tapestry can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the initial 180-day period, although Nasdaq may, in its discretion, require Tapestry to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that Tapestry has demonstrated the ability to maintain long-term compliance. If compliance is not achieved by June 16, 2008, Tapestry will be eligible for an additional 180-day compliance period if it meets the Nasdaq Capital Market initial listing criteria as set forth in Marketplace Rule 4310(c) other than the minimum bid price requirement. If Tapestry is not eligible for an additional compliance period, or does not regain compliance during any additional compliance period, Nasdaq will provide written notice to Tapestry that its securities will be delisted. At such time, Tapestry would be able to appeal the delisting determination to a Nasdaq Listing Qualifications Panel. There can be no assurance that Tapestry will be able to regain compliance with the Nasdaq listing requirements or that its securities will not be delisted from the Nasdaq Capital Market on a basis other than failure to maintain a minimum bid price. About Tapestry Pharmaceuticals, Inc. Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, TPI 287 is in multiple Phase 2 clinical studies at this time. For more information about Tapestry and its technologies, visit Tapestry's website at glink@tapestrypharma.comlilian@sternir.comtapestry@schwartz-pr.com CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer of Tapestry Pharmaceuticals, Inc., +1-303-516-8500, glink@tapestrypharma.com; or Investor: Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200, lilian@sternir.com, for Tapestry Pharmaceuticals, Inc.; or Media: Dana Conti of Schwartz Communications, +1-781-684-0770, tapestry@schwartz-pr.com, for Tapestry Pharmaceuticals, Inc. Web site:

MADISON, Wis., Oct. 3 /PRNewswire/ -- Cellectar LLC, (Cellectar), a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Ernest Allen as Director, Clinical Operations and LisaAnn Trembath as Manager of Medical Affairs. These appointments reflect the advancement of the company's lead product, CLR1404, toward clinical trials. Prior to joining Cellectar, Mr. Allen spent over 20 years in progressively senior positions in clinical operations for pharmaceutical companies including Alcon, Amgen, Parke-Davis and Origin Pharmaceuticals, Inc., a U.K.-based Clinical Research Organization (CRO), where he served as Senior Clinical Manager. Most recently, he was Clinical Manager for Tapestry Pharmaceuticals, Inc., a cancer treatment pharmaceutical company located in Boulder, CO. Ms. Trembath brings 21 years of experience as a nuclear medicine technologist specializing in medical imaging, including 10 years of clinical trials research experience and nine years in the radiopharmaceuticals industry. Immediately prior to joining Cellectar, Ms. Trembath was a Senior Clinical Affairs Specialist in the Medical Affairs Division at Bristol-Myers Squibb Medical Imaging, where she developed tools and educational programs for partner clinicians and field personnel. Prior to her position at BMS, she coordinated clinical trials research at the Medical College of Wisconsin and project management at Affiliated Research Centers. Bill Clarke, M.D., Cellectar's President and CEO, commented, "As we advance our lead product candidate, CLR1404, toward clinical trials, Ernest and LisaAnn bring the necessary clinical development skills needed for our progression. These highly experienced individuals are excellent additions to our team." CLR1404 is currently in preclinical development and the company expects to initiate Phase I clinical trails in mid-2008. About Cellectar Cellectar LLC is a radiopharmaceuticals company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells. Cellectar's products' unique mechanism of action is based on their selective accumulation and retention in malignant tumors and not normal cells. The company's operations are based in Madison, WI. Cellectar has previously raised approximately $9.0 million from angel investors; including Continuum Investment Partners. For further information about Cellectar, visit the company website at About CLR1404 Cellectar's lead product candidate, CLR1404, is a phospholipid ether (PLE) combined with the radiolabel 131Iodine. Preclinical studies have shown that this compound is selectively retained in malignant cells. In pre-clinical studies, CLR1404 was taken up and retained in 100% of the 40+ malignant tumor types tested. Cellectar plans to move the compound into phase I clinical trials in mid-2008. CONTACT: Pat Diamond of FD for Cellectar LLC, +1-617-747-3609 or pat.diamond@fd.com Web site:

BOULDER, Colo., April 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of up to $40,000,000 of its common stock. Banc of America Securities LLC will act as sole bookrunning manager for the offering. Needham & Company, LLC will act as co-lead manager and Rodman & Renshaw, LLC will act as co-manager for the offering. When available, copies of the preliminary prospectus related to the offering may be obtained from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001 or via e-mail at dg.prospectus_distribution@bofasecurities.com. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Further, this press release does not constitute either an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tapestry Pharmaceuticals, Inc. Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Contact: Tapestry Pharmaceuticals, Inc. Gordon Link Senior Vice President, Chief Financial Officer 303-516-8500 glink@tapestrypharma.com Elma Hawkins, Ph.D. Communications and Corporate Development 212-400-3019 ehawkins@tapestrypharma.com Investor: Lilian Stern Stern Investor Relations, Inc. 212-362-1200 lilian@sternir.com Tapestry Pharmaceuticals, Inc. CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,+1-303-516-8500, glink@tapestrypharma.com , or Elma Hawkins, Ph.D.,Communications and Corporate Development, +1-212-400-3019,ehawkins@tapestrypharma.com , both of Tapestry Pharmaceuticals, Inc.; orInvestors, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200,lilian@sternir.com